Safety and Efficacy of Biologic Therapies (Ustekinumab and Vedolizumab) in the Treatment of Inflammatory Bowel Disease (IBD): A Systematic Review.

Cureus · 2023 · PMC10698389 · PMID 38060699

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a notable trendno p-value reported

The findings revealed a notable trend: ustekinumab displayed a propensity for yielding higher rates of clinical remission in patients with ulcerative colitis (UC).

also in 2,380 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.